Shares shifted sharply higher as Neuronetics delivered a third-quarter earnings report that cleared every hurdle Wall Street had set. Revenue hit $42.0 million, up 12.5% year-over-year, exceeding analyst estimates of $40.43 million.

The net loss per share of $0.02 crushed the consensus forecast of -$0.09. The stock surged to $2.65, a gain of roughly 17.5%, extending a rally that began a day earlier with a 9.71% pop — yet even after this run, shares still sit well below analyst price targets ranging from $3 to $7.

  • The Clinic Business Is Doing the Heavy Lifting. Greenbrook clinic revenue — the company's network of mental-health treatment centers — rose 20.1% to $26.2 million , accounting for the bulk of the top-line beat. Meanwhile, revenue from the company's brain-stimulation device itself grew only about 2% to $15.8 million. That lopsided mix matters: the clinics now represent roughly 62% of total sales, meaning Neuronetics' growth story increasingly depends on filling therapy chairs, not shipping hardware.

  • Margins Improved Faster Than Anyone Expected. Gross margin — the share of revenue left after direct costs — jumped to 52.2% from 45.9% a year ago , a 630-basis-point swing driven by better billing practices and smarter patient qualification at clinics. Management raised full-year gross-margin guidance to 49%–50%, up from 48%–50% , a modest but telling signal that the efficiency gains are durable rather than one-off.

  • Positive Adjusted EBITDA Is a Milestone — With Caveats. Adjusted EBITDA — a proxy for operating cash flow before certain charges — hit $1.9 million, a $6.6 million improvement from a $4.7 million loss a year ago. That's the headline. The fine print: full-year cash outflow from operations and investing is still guided at $(10) million to $(12) million , and cash on hand fell to $27.9 million from $34.5 million a year earlier.

A going-concern flag tied to debt covenants surfaced in the prior quarter's filing , making the cash trajectory a critical watchpoint.

  • Revenue Guidance Held Steady — A Double-Edged Signal. Full-year revenue guidance remains $160 million–$164 million , unchanged despite Q3's beat. That conservatism could reflect seasonal caution or signal that management sees limited upside in Q4. With the market cap around $172 million, investors are essentially paying about 1× sales for a company still burning cash — a valuation that prices in hope but not proof of sustained profitability.